NCT06504524View on ClinicalTrials.gov

A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US

CompletedOBSERVATIONAL
Enrollment

633

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions
Multiple Myeloma
Interventions
DRUG

Elranatamab

BCMA-CD3 bispecific antibody

DRUG

Standard of Care

control arm

Trial Locations (2)

10001

Pfizer, New York

Unknown

Pfizer, Berlin

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06504524 - A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US | Biotech Hunter | Biotech Hunter